

3-1-06

Ifw



Attorney Docket No. TOMK0004
Client/Matter No. 20617.0004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	10/520,771	Confirmation No.	9945
Applicant:	Mohammad Reza MEHRABI	Title:	USE OF ALPROSTADIL (PROSTAGLANDIN E1) FOR PRODUCING A MEDICAMENT FOR ANGIOGENESIS
Filed:	December 5, 2005		
TC/A.U.	1615		
Examiner:			
Docket No.	TOMK0004		
Customer No.	25235		

CERTIFICATE OF MAILING BY EXPRESS MAIL

Commissioner for Patents
Alexandria, VA 22313-1450


Sir:

The undersigned hereby certifies that the attached

1. IDS, Form PTO/SB/08a and copies of References;
2. Return Card, and


this Certificate of Mailing relating to the above application, were deposited as "Express Mail," Mailing Label No. EL890827545US with the U.S. Postal Service, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 28, 2006.

February 28, 2006



Mailer

February 28, 2006



Carol W. Burton, Reg. No. 35,465
Hogan & Hartson L.L.P.
1200 17th Street, Suite 1500
Denver, CO 80202
Telephone: (303) 454-2454
Facsimile: (303) 899-7333



Attorney Docket No. TOMK0004
Client/Matter No. 20617.0004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. 10/520,771

Applicant: Mohammad Reza MEHRABI

Filed: December 5, 2005

TC/A.U. 1615

Examiner:

Docket No. TOMK0004

Customer No. 25235

Confirmation No. 9945

Title: USE OF ALPROSTADIL
(PROSTAGLANDIN E1)
FOR PRODUCING A
MEDICAMENT FOR
ANGIONEogenesis

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Applicant hereby submits for filing under 37 CFR 1.97 a disclosure statement. In submitting the references listed, no representation is made or implied that the references are or are not material to the examination of this application. The patents, publications or other information of which Applicants are presently aware are listed in Form PTO/SB/08A submitted herewith. Copies of non-U.S. references are enclosed.

No fee is believed due for this submittal. However, any fee deficiency associated with this submittal may be charged to Deposit Account No. 50-1123.

Respectfully submitted,

February 28, 2006


Carol W. Burton, Reg. No. 35,465
Hogan & Hartson L.L.P.
1200 17th Street, Suite 1500
Denver, Colorado 80202
(303) 454-2454 (telephone)
(303) 899-7333 (facsimile)



PTO/SB/08a(08/03)

Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/520,771	
			Filing Date	December 5, 2005	
			First Named Inventor	Mohammad Reza MEHRABI	
			Art Unit	1615	
			Examiner Name		
Sheet	1	of	2	Attorney Docket No.	TOMK0004

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document No. No. – Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵				

**EXAMINER
SIGNATURE****DATE
CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet

1

Q

2

Application Number

10/520,771

Filing Date

December 5, 2005

First Named Inventor

Mohammad Reza MEHRABI

Art Unit

1615

Examiner Name _____

Attorney Docket No.

TOMK0004

Examiner
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published

 τ^2

International Search Report: Application No. PCT/AT 00/00252

DIAZ-FLORES, ET AL., "Intense Vascular Sprouting From Rat Femoral Vein Induced by Prostaglandins E1 and E2"; The Anatomical Record; January 1994; pp. 68-76; Vol. 238; Wiley-Liss, Inc.

KÖPF-MAIER, ET AL., "Influence of dispass and angiogenesis factors on the growth of human xenografts": *Journal of Cancer Research and Clinical Oncology*; 1988; pp. 547-552; Vol. 114.

GULLINO, "PROSTAGLANDINS AND GANGLIOSIDES OF TUMOR MICROENVIRONMENT: THEIR ROLE IN ANGIOGENESIS"; Acta Oncologica; 1995; pp. 439-441; Vol. 34, No. 3; Scandinavian University Press.

COHEN, MD., "Erythromelalgia: New theories and new therapies"; *Journal of American Academy of Dermatology*; 2000; pp. 841-847.

DATE
CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.